{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:34:07Z","timestamp":1792593247044,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcin.2024.08.027","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T14:07:22Z","timestamp":1732543642000},"page":"2639-2663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"title":["International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"17","author":[{"given":"Dominick J.","family":"Angiolillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Alexopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Bonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa H.","family":"Cavallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Cuisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-9575","authenticated-orcid":false,"given":"Jose Luis","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8503-5736","authenticated-orcid":false,"given":"Francesco","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0403-3726","authenticated-orcid":false,"given":"Young-Hoon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-8351","authenticated-orcid":false,"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos D.","family":"Rizas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Rollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek Y.F.","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-6229","authenticated-orcid":false,"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udaya S.","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien Ten","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-9226","authenticated-orcid":false,"given":"Ron","family":"Waksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2024.08.027_bib1","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet therapy after percutaneous coronary intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.027_bib2","first-page":"804","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib3","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2023.131340","article-title":"Temporal variations in ischemic and bleeding event risks after acute coronary syndrome during dual antiplatelet therapy","author":"Fujii","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.31083\/j.rcm2308286","article-title":"Bleeding complications in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2217\/pgs-2022-0057","article-title":"Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcin.2024.08.027_bib7","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib8","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/eurheartj\/ehad362","article-title":"Personalised antiplatelet therapies for coronary artery disease: what the future holds","volume":"44","author":"Capodanno","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tcm.2021.12.007","article-title":"Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention","volume":"33","author":"Galli","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41569-021-00549-w","article-title":"Pharmacogenetics to guide cardiovascular drug therapy","volume":"18","author":"Duarte","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib11","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Virani","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jacc.2021.09.005","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib16","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/09537100120058739","article-title":"The P2Y12 receptor as a therapeutic\u00a0target in cardiovascular disease","volume":"12","author":"Storey","year":"2001","journal-title":"Platelets"},{"key":"10.1016\/j.jcin.2024.08.027_bib19","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Dav\u00ec","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","article-title":"Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials","volume":"142","author":"Navarese","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2014.156","article-title":"Novel antiplatelet agents in acute coronary syndrome","volume":"12","author":"Franchi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib22","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib24","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/eurheartj\/ehp159","article-title":"Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial","volume":"30","author":"Michelson","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy","volume":"56","author":"Storey","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib26","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicenter registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/eurheartj\/ehn046","article-title":"Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation","volume":"29","author":"Price","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib29","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2011.06.059","article-title":"Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data","volume":"58","author":"Brar","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2011.04.017","article-title":"High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes","volume":"58","author":"Bonello","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib31","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1093\/eurheartj\/ehv744","article-title":"A\u00a0head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study","volume":"37","author":"Rollini","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib32","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/eurheartj\/ehz202","article-title":"Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial","volume":"40","author":"Aradi","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib33","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1160\/TH09-11-0799","article-title":"Platelet function testing and risk of bleeding complications","volume":"103","author":"Ferreiro","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.027_bib34","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/eurheartj\/ehab836","article-title":"Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials","volume":"43","author":"Galli","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","article-title":"Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window","volume":"56","author":"Sibbing","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib36","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.jcin.2015.08.032","article-title":"Is there an ideal level of platelet P2Y12-receptor inhibition in patients undergoing percutaneous coronary intervention?: \"window\" analysis from the ADAPT-DES study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)","volume":"8","author":"Kirtane","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jcin.2024.08.027_bib38","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib39","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jacc.2013.07.110","article-title":"Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction","volume":"63","author":"Perl","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.007811","article-title":"Clopidogrel pharmacogenetics","volume":"12","author":"Pereira","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of antiplatelet therapy","volume":"63","author":"Castrichini","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jcin.2024.08.027_bib42","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2024.08.027_bib43","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib44","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib45","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1008410","article-title":"Effects of CYP2C19 genotype on outcomes of clopidogrel treatment","volume":"363","author":"Par\u00e9","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib46","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","article-title":"CYP2C19\u22172 and \u221717 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome","volume":"5","author":"Cuisset","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","article-title":"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19","volume":"22","author":"Scott","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.jcin.2024.08.027_bib48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"},{"key":"10.1016\/j.jcin.2024.08.027_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2024.08.027_bib50","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ahj.2010.12.011","article-title":"The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy","volume":"161","author":"Gurbel","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib51","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jth.12342","article-title":"The CYP2C19\u221717 variant is not independently associated with clopidogrel response","volume":"11","author":"Lewis","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.027_bib52","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19\u221717 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib53","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/cpt.2039","article-title":"Impact of the CYP2C19\u221717 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"109","author":"Lee","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.08.027_bib54","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jmoldx.2018.01.011","article-title":"Recommendations for clinical CYP2C19 genotyping allele selection: a report of the association for molecular pathology","volume":"20","author":"Pratt","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jcin.2024.08.027_bib55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/17512433.2021.1927709","article-title":"Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations","volume":"14","author":"Galli","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jcin.2024.08.027_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.991646","article-title":"Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy","volume":"9","author":"Nguyen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib57","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1177\/0091270009355161","article-title":"Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans","volume":"50","author":"Man","year":"2010","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jcin.2024.08.027_bib58","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0040-1718729","article-title":"The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease","volume":"121","author":"Kim","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.027_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacasi.2021.12.005","article-title":"Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations","volume":"2","author":"Kwon","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.jcin.2024.08.027_bib60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","volume":"56","author":"Holmes","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib62","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.08.027_bib63","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib64","first-page":"173","article-title":"Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines","volume":"13","author":"Landi","year":"2024","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jcin.2024.08.027_bib65","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/CIRCULATIONAHA.124.069012","article-title":"Demystifying the myth of 12-month dual antiplatelet therapy after acute coronary syndrome","volume":"150","author":"Valgimigli","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib66","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jacc.2014.06.1170","article-title":"Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease","volume":"64","author":"Angiolillo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib67","doi-asserted-by":"crossref","first-page":"20a","DOI":"10.1016\/j.amjcard.2008.11.019","article-title":"Methods for the measurement of platelet function","volume":"103","author":"Michelson","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/17512433.2017.1353909","article-title":"Role of genetic testing in patients undergoing percutaneous coronary intervention","volume":"11","author":"Moon","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jcin.2024.08.027_bib69","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12967-018-1469-8","article-title":"Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention","volume":"16","author":"Cavallari","year":"2018","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib70","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cpt.1006","article-title":"Multisite investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy","volume":"104","author":"Empey","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.08.027_bib71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/pgs-2017-0028","article-title":"Institutional profile: University of Florida Health Personalized Medicine Program","volume":"18","author":"Cavallari","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jcin.2024.08.027_bib72","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib73","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A\u00a0genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib74","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2020.02.009","article-title":"Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes","volume":"5","author":"Franchi","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jcin.2024.08.027_bib75","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(17)32279-1","article-title":"Dual antiplatelet therapy guided by platelet function testing","volume":"390","author":"Angiolillo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib76","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/eurheartj\/ehr458","article-title":"Toward a therapeutic window for antiplatelet therapy in the elderly","volume":"33","author":"Gurbel","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib77","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/tpj.2015.17","article-title":"A\u00a0prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study","volume":"16","author":"So","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jcin.2024.08.027_bib79","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jama.2011.1332","article-title":"High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI","volume":"306","author":"Parodi","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2024.08.027_bib80","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","article-title":"Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib81","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib82","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib83","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcin.2023.01.363","article-title":"Clinical impact of CYP2C19 genotype on clopidogrel-based antiplatelet therapy after percutaneous coronary intervention","volume":"16","author":"Lee","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib84","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1055\/a-1346-3300","article-title":"Pharmacodynamic profile and prevalence of bleeding episode in east asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial","volume":"121","author":"Jeong","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.027_bib85","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.006243","article-title":"Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents","volume":"11","author":"Maehara","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib86","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FJC.0000000000000337","article-title":"Clinical value of CYP2C19 genetic testing for guiding the antiplatelet therapy in a Chinese population","volume":"67","author":"Shen","year":"2016","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jcin.2024.08.027_bib87","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ehjcvp\/pvad085","article-title":"Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.027_bib88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/cpt.2776","article-title":"Evaluation of potential racial disparities in CYP2C19-guided P2Y(12) inhibitor prescribing after percutaneous coronary intervention","volume":"113","author":"Cavallari","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.08.027_bib89","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","article-title":"Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study","volume":"59","author":"Price","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib90","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","article-title":"Basic principles of platelet biology and clinical implications","volume":"74","author":"Angiolillo","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.jcin.2024.08.027_bib91","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.120.045465","article-title":"Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus","volume":"142","author":"Capodanno","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib92","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41569-018-0080-2","article-title":"Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs","volume":"16","author":"Patti","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12265-013-9449-0","article-title":"Platelet function profiles in patients with diabetes mellitus","volume":"6","author":"Rollini","year":"2013","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jcin.2024.08.027_bib94","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/CIRCULATIONAHA.116.023402","article-title":"Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 study","volume":"134","author":"Franchi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib96","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cpt.2612","article-title":"Impact of the ABCD-GENE score on clopidogrel clinical effectiveness after PCI: a multi-site, real-world investigation","volume":"112","author":"Thomas","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.08.027_bib97","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jacc.2024.02.015","article-title":"Effectiveness of clopidogrel vs alternative P2Y(12) inhibitors based on the ABCD-GENE score","volume":"83","author":"Thomas","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib98","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease","volume":"306","author":"Mega","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2024.08.027_bib99","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijcard.2010.12.083","article-title":"The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial)","volume":"157","author":"Ari","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib100","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib101","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jcin.2008.08.018","article-title":"Glycoprotein IIb\/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study","volume":"1","author":"Cuisset","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib102","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/CIRCULATIONAHA.108.833236","volume":"119","author":"Valgimigli","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib103","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/clc.20884","article-title":"Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance","volume":"34","author":"Wang","year":"2011","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib104","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1160\/TH13-10-0874","article-title":"A\u00a0comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry","volume":"112","author":"Mayer","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.027_bib105","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib106","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/AC.71.3.3152091","article-title":"High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-center trial","volume":"71","author":"Zhang","year":"2016","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib107","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.amjcard.2008.08.048","article-title":"Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis","volume":"103","author":"Bonello","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib108","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2362.2011.02594.x","article-title":"Justification of 150\u00a0mg clopidogrel in patients with high on-clopidogrel platelet reactivity","volume":"42","author":"Aradi","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jcin.2024.08.027_bib109","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/j.ijcard.2012.05.100","article-title":"Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis","volume":"167","author":"Aradi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib110","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"Price","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2024.08.027_bib111","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","article-title":"Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study","volume":"115","author":"Angiolillo","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jcin.2024.08.027_bib112","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ehjcvp\/pvae036","article-title":"Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.027_bib113","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib114","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s12471-016-0873-z","article-title":"Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands","volume":"24","author":"Deiman","year":"2016","journal-title":"Neth Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib115","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jacc.2013.12.023","article-title":"Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel","volume":"63","author":"Aradi","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib116","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib117","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib118","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.12659\/MSM.903054","article-title":"Effects of dual-dose clopidogrel, clopidogrel combined with tongxinluo capsule, and ticagrelor on patients with coronary heart disease and CYP2C19\u22172 gene mutation after percutaneous coronary interventions (PCI)","volume":"23","author":"Chen","year":"2017","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jcin.2024.08.027_bib119","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcin.2017.07.022","article-title":"Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Cavallari","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib120","first-page":"29","article-title":"Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study","volume":"68","author":"Ogawa","year":"2016","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib121","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jcin.2020.01.219","article-title":"Routine CYP2C19 genotyping to adjust thienopyridine treatment after primary PCI for STEMI: results of the GIANT study","volume":"13","author":"Hulot","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib122","article-title":"CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention in diverse clinical settings","volume":"11","author":"Beitelshees","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jcin.2024.08.027_bib123","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib124","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jcin.2024.08.027_bib125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jcin.2023.01.356","article-title":"Genetic-guided oral P2Y(12) inhibitor selection and cumulative ischemic events after percutaneous coronary intervention","volume":"16","author":"Ingraham","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib126","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcin.2021.01.024","article-title":"Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y(12) inhibitor therapy: a meta-analysis","volume":"14","author":"Pereira","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijcard.2021.10.010","article-title":"Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization","volume":"345","author":"Galli","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib128","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicenter trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib129","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(16)31323-X","article-title":"Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial","volume":"388","author":"Cayla","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib130","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib131","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib132","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ehjcvp\/pvz059","article-title":"Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial","volume":"6","author":"Zheng","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.027_bib133","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","article-title":"Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial","volume":"71","author":"Notarangelo","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib134","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2021.08.051","article-title":"Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients","volume":"343","author":"Al-Rubaish","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib135","article-title":"Prospective CYP2C19 genotyping to guide antiplatelet therapy following percutaneous coronary intervention: a pragmatic randomized clinical trial","volume":"13","author":"Tuteja","year":"2020","journal-title":"Circulation Genom Precis Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib136","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijcard.2016.09.088","article-title":"Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent","volume":"225","author":"S\u00e1nchez-Ramos","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib137","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.118.002258","article-title":"Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention","volume":"11","author":"Lee","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jcin.2024.08.027_bib138","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1016\/j.ijcard.2013.06.014","article-title":"Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial","volume":"168","author":"Xie","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib139","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","article-title":"Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study","volume":"167","author":"Siller-Matula","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-012-0684-z","article-title":"Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention","volume":"34","author":"Hazarbasanov","year":"2012","journal-title":"J\u00a0Thromb Thrombol"},{"key":"10.1016\/j.jcin.2024.08.027_bib141","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(21)00728-5","article-title":"Guided P2Y(12) inhibitor therapy after percutaneous coronary intervention","volume":"397","author":"Sibbing","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2024.08.027_bib142","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehs059","article-title":"The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study","volume":"33","author":"Bhatt","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib143","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y(12) inhibitor or aspirin monotherapy for secondary prevention of coronary events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib144","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1\u00a0week","volume":"43","author":"De Caterina","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib145","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib146","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2\u00a0months of dual antiplatelet therapy with 12\u00a0months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib147","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","article-title":"Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial","volume":"141","author":"Lopes","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib148","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ehjcvp\/pvz030","article-title":"Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy","volume":"6","author":"Galli","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"10.1016\/j.jcin.2024.08.027_bib149","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/ehjcvp\/pvae057","article-title":"P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.027_bib150","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.jcin.2024.03.027","article-title":"P2Y12 inhibition in patients requiring oral anticoagulation after percutaneous coronary intervention: the SWAP-AC-2 study","volume":"17","author":"Ortega-Paz","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib151","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41397-020-0162-5","article-title":"Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data","volume":"20","author":"Limdi","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jcin.2024.08.027_bib152","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40256-021-00496-4","article-title":"Cost effectiveness of a CYP2C19 genotype-guided strategy in patients with acute myocardial infarction: results from the POPular genetics trial","volume":"22","author":"Claassens","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jcin.2024.08.027_bib153","doi-asserted-by":"crossref","first-page":"175","DOI":"10.15420\/ecr.2018.29.2","article-title":"Cost-effectiveness of platelet function-guided strategy with clopidogrel or ticagrelor","volume":"14","author":"Lomakin","year":"2019","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib154","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2019.07.030","article-title":"Impaired spontaneous\/endogenous fibrinolytic status as new cardiovascular risk factor?: JACC Review Topic of the Week","volume":"74","author":"Gorog","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib155","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib156","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehad088","article-title":"Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction","volume":"44","author":"Lee","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib157","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/ehjcvp\/pvab068","article-title":"Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis","volume":"8","author":"Tavenier","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.027_bib158","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.011990","article-title":"Comparison of unguided de-escalation versus guided selection of dual antiplatelet therapy after acute coronary syndrome: a systematic review and network meta-analysis","volume":"15","author":"Kuno","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib159","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4244\/EIJ-E-23-00022","article-title":"DAPT guided by platelet function tests or genotyping after PCI: pros and cons","volume":"19","author":"Angiolillo","year":"2023","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jcin.2024.08.027_bib160","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehac829","article-title":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis","volume":"44","author":"Kang","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2024.08.027_bib161","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2021.11.028","article-title":"Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes","volume":"15","author":"Laudani","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jcin.2024.08.027_bib162","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/cpt.3026","article-title":"High platelet reactivity combined with CYP2C19 genotype in predicting outcomes in East Asian patients undergoing percutaneous coronary intervention","volume":"114","author":"Kim","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcin.2024.08.027_bib163","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ehjcvp\/pvae019","article-title":"De-escalation versus shortening of DAPT","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jcin.2024.08.027_bib164","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jacc.2019.03.470","article-title":"Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC Review Topic of the Week","volume":"73","author":"Arora","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2024.08.027_bib165","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1055\/s-0038-1641153","article-title":"Platelet inhibition and bleeding in patients undergoing non-cardiac surgery-the BIANCA observational study","volume":"118","author":"Mahla","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.027_bib166","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jth.12505","article-title":"Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification","volume":"12","author":"Price","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jcin.2024.08.027_bib167","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International Expert Consensus on switching platelet P2Y(12) receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2024.08.027_bib168","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879824011142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879824011142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T14:43:44Z","timestamp":1786027424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879824011142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":168,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1936879824011142"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2024.08.027","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2024.08.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}